A Phase 3 interventional study of TH07 and TH07 in Androgenic Alopecia, sponsored by Triple Hair Inc. Recruiting at 1 site in Canada. Open to male participants aged 18 Years to 49 Years. Per ClinicalTrials.gov, last updated 2026-03-16.
Sponsored by Triple Hair Inc · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Alopecia with a site in Canada — 4 open to participants now, 5 under way, 4 of them phase 3. Alopecia · Canada.
Among the 18 studies in Alopecia with a site in Canada, this one is the 8th largest by planned enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2026, is one of 7 in phase 3, and was the 17th registered.
512 studies on the registry are indexed under Alopecia; 129 are open to participants now.
Browse Alopecia studies →4 of the 18 studies in Alopecia with a site in Canada are open now. Recruiting first, the newest first:
Pelage Pharmaceuticals, Inc. · Sites in Canada, United States
Ages 18–55 · Men only
Pfizer · Sites in Canada, United States, China and 8 more countries
Ages 12+
Eli Lilly and Company · Sites in Canada, United States, Argentina and 9 more countries
Ages 6–17
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 75 Alopecia studies recruiting now, 25 (33%) set no upper age limit and 46 (61%) stop at 75 or younger; 9 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 49 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 9
First in 2002; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 420 is above the median of 50 across 431 interventional studies indexed under Alopecia.
Median enrollment 322 across the 17 interventional studies. Of the 10 that completed or were terminated, 8 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 18 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Triple Hair Inc as lead sponsor.
Triple Hair Inc has 1 study filed under Alopecia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 18 studies in Alopecia with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn whether a new topical solution, TH07, can help treat androgenic alopecia in men and to learn more about its safety. Participants will be asked to apply either the TH07 solution, a standard hair growth treatment (Minoxidil 5%), or a placebo every day for 24 weeks. At the end of the study, hair growth will be compared in each group to determine which treatment is most effective at increasing hair count.
The MATT study is a Phase III clinical trial designed to evaluate the safety and effectiveness of a new topical hair growth treatment called TH07.
TH07 is a combined topical spray solution containing three active ingredients commonly used to treat hair loss: Minoxidil (5%) Finasteride (0.1%) and Latanoprost (0.03%). The study plans to enroll 420 men aged 18 to 49 years old across up to 10 clinical sites.
Participants will be randomly assigned to one of four groups to receive either TH07 (once or twice daily), a standard Minoxidil solution, or a placebo.
The treatment will be applied daily (once or twice) for 24 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Willing to comply with the following restrictions for the duration of trial participation:
Participation in any other drug or device trials during the course of this trial.
Note: However, the following shall be permissible:
Exclusion Criteria:
History of scalp treatment including though not limited to any of the following:
5-Any other surgical treatment for hair loss
Any of the following hair styles:
1.Shaved scalp. 2-Use of occlusive wig, hair extensions, non- breathable wigs.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants in Arm A will apply TH07 topical solution twice a day for 24 weeks
Drug: TH07
All participants in Arm B will apply TH07 topical solution once a day and Placebo topical solution once a day for 24 weeks
Drug: TH07
All participants in Arm C will apply Minoxidil 5% topical solution twice a day for 24 weeks
Drug: Minoxidil 5% Topical Solution
All participants in Arm D will apply Placebo topical solution twice a day for 24 weeks
Other: Placebo
TH07 (5%Minoxidil, 0.1%Finasteride, 0.03%Latanoprost); topical solution; twice a day
* TH07 (5%Minoxidil, 0.1%Finasteride, 0.03%Latanoprost); topical solution; once a day * Placebo; topical solution; once a day
Minoxidil 5%; topical solution; twice a day
Placebo; topical solution; twice a day
Non-vellus hair count
Number of hair in the matched target area measured by phototrichogram
Time frame: Baseline and week 24
Hair diameter and cumulative hair thickness
hair thickness is defined as average hair diameter \* hair count in the matched target area / size of matched target area (mm/cm2)
Time frame: Baseline and week 24
Subject-reported improvement
self-assessment questionnaire
Time frame: week 24
Non-vellus hair count
in the matched target area by phototrichogram between TH07 twice daily, TH07 once daily, and placebo
Time frame: Baseline and week 24
Incidence of treatment related adverse events.
reporting of adverse events and serious adverse events
Time frame: through study completion, average 28 weeks
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Apr 2026; primary completion for Dec 2027, 20 months later.
Of 28 phase 3 interventional studies under Alopecia, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 59. This study's planned 20 months is close to that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.